文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

炎症性皮肤病治疗结果中性别差异的系统评价:是时候制定新指南了吗?

A systematic review of sex and gender differences in treatment outcome of inflammatory skin diseases: Is it time for new guidelines?

作者信息

Preis S, Ziehfreund S, Biedermann T, Horster S, Zink A

机构信息

Department of Dermatology and Allergy, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.

Institute for Medical Information Processing, Biometry, and Epidemiology, Pettenkofer School of Public Health LMU Munich, Munich, Germany.

出版信息

J Eur Acad Dermatol Venereol. 2025 Mar;39(3):512-528. doi: 10.1111/jdv.20256. Epub 2024 Jul 30.


DOI:10.1111/jdv.20256
PMID:39078087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11851263/
Abstract

BACKGROUND: Gender- and sex-specific differences in medicine were long-time disregarded. Despite numerous indications of gender- and sex-specific influences on the treatment of dermatological conditions, these have not yet been systematically investigated. OBJECTIVES: To meet this unmet need, we conducted the present systematic review on the topic of gender and sex differences in the treatement outcome of skin diseases. METHODS: Embase (via Ovid), PubMed Medline and Web of Science were searched, in between January 2001 and December 2022. English and german randomized controlled trials, prospective and retrospective cohorts and case-control studies that examined differences between men and women in treatment outcomes of skin diseases were included. RESULTS: Two authors independently screened the reports for eligibility, one extracted all data (the second double-checked) and critically appraised the quality and risk of bias of the studies. Eighty-three reports were included. The largest share of the identified publications focused on gender differences in psoriasis and psoriatic arthritis (n = 49), followed by melanoma (n = 8) and sporadic studies (n < 5) of inflammatory, infectious and autoimmune skin diseases. The main topics in which gender differences could be identified were choice of treatment, time to initiation of treatment, therapy response, adverse events, adherence and treatment satisfaction. For psoriasis, gender differences could be found in all aspects, while for the other skin diseases specific publications on gender differences are still missing. CONCLUSIONS: This systematic review shows numerous gender differences but also reveals major gaps in gender-specific care in dermatology which should be narrowed in the upcoming years to optimize a patient-centred, individualized, gender-equal healthcare. PROSPERO Registration: CRD42022306626.

摘要

背景:医学中性别和性别的特异性差异长期以来一直被忽视。尽管有大量迹象表明性别特异性对皮肤病治疗有影响,但尚未对其进行系统研究。 目的:为满足这一未被满足的需求,我们对皮肤病治疗结果中的性别差异这一主题进行了本次系统评价。 方法:检索了2001年1月至2022年12月期间的Embase(通过Ovid)、PubMed Medline和Web of Science。纳入了英语和德语的随机对照试验、前瞻性和回顾性队列研究以及病例对照研究,这些研究探讨了男性和女性在皮肤病治疗结果方面的差异。 结果:两位作者独立筛选报告的合格性,一位提取所有数据(另一位进行二次核对)并严格评估研究的质量和偏倚风险。共纳入83篇报告。已识别出版物中最大比例聚焦于银屑病和银屑病关节炎的性别差异(n = 49),其次是黑色素瘤(n = 8)以及关于炎症性、感染性和自身免疫性皮肤病的零星研究(n < 5)。能够识别出性别差异的主要主题包括治疗选择、开始治疗的时间、治疗反应、不良事件、依从性和治疗满意度。对于银屑病,在各个方面都能发现性别差异,而对于其他皮肤病,关于性别差异的具体出版物仍然缺失。 结论:本系统评价显示了众多性别差异,但也揭示了皮肤科性别特异性护理方面的重大差距,未来几年应缩小这些差距,以优化以患者为中心、个性化、性别平等的医疗保健。PROSPERO注册号:CRD42022306626。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185c/11851263/95705d40199e/JDV-39-512-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185c/11851263/95705d40199e/JDV-39-512-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185c/11851263/95705d40199e/JDV-39-512-g001.jpg

相似文献

[1]
A systematic review of sex and gender differences in treatment outcome of inflammatory skin diseases: Is it time for new guidelines?

J Eur Acad Dermatol Venereol. 2025-3

[2]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2020-1-9

[3]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[4]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2017-12-22

[5]
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.

Health Technol Assess. 2024-10

[6]
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].

Epidemiol Prev. 2013

[7]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[8]
Eliciting adverse effects data from participants in clinical trials.

Cochrane Database Syst Rev. 2018-1-16

[9]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2022-5-23

[10]
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.

Cochrane Database Syst Rev. 2025-3-27

引用本文的文献

[1]
Investigating demographic differences in women's dermatologic concerns: a large urban cohort study.

Int J Womens Dermatol. 2025-9-5

本文引用的文献

[1]
Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry.

J Psoriasis Psoriatic Arthritis. 2022-7

[2]
Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience.

Dermatol Ther. 2022-12

[3]
A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis.

Dermatol Ther (Heidelb). 2022-10

[4]
The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex.

J Cancer Res Clin Oncol. 2023-7

[5]
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

An Bras Dermatol. 2022

[6]
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL).

Melanoma Res. 2022-10-1

[7]
Therapeutic failure in moderate and severe psoriasis patients in a health institution - a transversal study of prevalence and demographic determinants.

J Dermatolog Treat. 2022-9

[8]
Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.

Dermatol Ther (Heidelb). 2022-6

[9]
Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care.

PLoS One. 2022

[10]
Sex Differences in the Patterns of Systemic Agent use Among Patients With Psoriasis: A Retrospective Cohort Study in Quebec, Canada.

Front Pharmacol. 2022-2-15

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索